This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis was based on intention to treat with all patients included in the study being accounted for in the analysis. The primary health outcome was health-related quality of life, assessed using the EuroQol EQ-5D classification, completed by each patient at baseline (after randomisation) and at 3, 6, and 12 months, and combined with survival to calculate quality-adjusted life-years (QALYs). Utility data were missing for 21 patients (13 in the TMLR group and 8 in the medical management group) and interpolation techniques were used to derive these data. No statistically significant difference was found between the study groups in terms of age, gender, perioperative mortality and survival at 12 months, (p=0.14).
Effectiveness results
12-month survival was 89% (95% CI: 83 -96) for the TMLR group and 96% (95% CI: 92 -100) for the medical management group, (p=0.14). (Results from the previous publication of the trial -see Other Publications of Related Interest below). Utility scores were statistically significantly higher in the TMLR group in comparison with the medical management group at 3 and 6 months. However, at 12 months the mean QALY per patient was 0.486 (95% CI: 0.429 -0.528) in the TMLR group and 0.447 (95% CI: 0.393 -0.492) in the medical management group, and the QALY difference of 0.039 (95% CI: -0.033 -0.113), corresponding to an extra 2 weeks of perfect health, was not statistically significant.
Clinical conclusions
Although patients undergoing TMLR experienced faster improvements in their health status, at the end of the study period, both the interventions produced similar QALY scores.
Measure of benefits used in the economic analysis
The benefit measure used in the economic analysis was represented by the QALY scores estimated in the effectiveness analysis.
Direct costs
No discounting was carried out, as the time horizon of the analysis was one year. Unit costs and quantities of resources were not reported separately. The cost/resource boundary adopted was that of the NHS. The cost items included in the analysis were the costs associated with the TMLR procedure (such as pre-procedural assessment, CO2 laser equipment, inpatient resource use, and post-procedure follow-up), the cost of cardiac related medication, and the cost of cardiac and non-cardiac related inpatient and outpatient episodes. Estimation of quantities was derived from the trial, while estimation of costs was mainly based on actual data derived from the Finance Department and Pharmacy at the Papworth Hospital. Costs estimated from different sources were adjusted to reflect NHS costs. Quantities of resources were collected during the trial (October 1993 to September 1997) and 1998/1999 prices were used.
